The U.S. Department of Defense (DoD) has selected Emergard as a potential candidate for a nerve agent antidote delivery system.
The system, which is developed by Emergent BioSolutions Inc., will be tested by the DoD and the DoD’s defense prime contractor, Batelle.
“We are pleased that our Emergard platform has been selected by DoD and Battelle for testing and development to address U.S. military auto-injector needs,” Adam Havey, executive vice president of Emergent BioSolutions, said.
The testing will be conducted under a contract with Batelle, and the project will be supported by the Defense Technical Information Center. This center is the biggest resource for the DoD and its development and research, as well as engineering and technical information. Emergard will also be developed to specifications under U.S. military guidelines.
“The Emergard platform, which is designed for intramuscular self-injection of antidotes and other emergency response medical treatments for nerve agents and other chemical threats, is another example of Emergent’s commitment to protecting lives and being a global leader in the development and manufacture of medical countermeasures that address biological and chemical threats as well as emerging infectious diseases,” Havey said.